To investigate the potential mechanism of the acquired resistance of anti-BRAF/EGFR therapy to BRAFV600E-mutant mCRC, we first employed operative tumor tissue derived from untreated BRAFV600E-mutant mCRC patients with liver metastasis to establish patient-derived xenograft (PDX) models to thoroughly assess the progressive resistance of encorafenib/cetuximab treatment on BRAFV600E-mutant mCRC (Figure 1A). Here, BRAF is linked to neoplasm.